AgeX Therapeutics Reports Merger-Related Financial Obligations, Equity Sales
Ticker: SER · Form: 8-K · Filed: Feb 6, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Agex Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2024 |
| Risk Level | medium |
| Pages | 11 |
| Reading Time | 13 min |
| Key Dollar Amounts | $0.0001, $500,000, $12.00 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: merger, equity-sales, debt, corporate-change
TL;DR
**AgeX is moving forward with its merger, creating new debt and selling stock.**
AI Summary
AgeX Therapeutics, Inc. filed an 8-K on February 6, 2024, reporting events from February 1, 2024, related to its ongoing merger with Serina Therapeutics, Inc. This filing indicates the creation of a direct financial obligation, unregistered sales of equity securities, and changes in control of the registrant, all stemming from the merger agreement. This matters to investors because these actions are critical steps in the merger process, which will significantly alter the company's structure and future prospects, potentially impacting stock value.
Why It Matters
This filing signals the progression of AgeX Therapeutics' merger with Serina Therapeutics, which will fundamentally change the company's business and financial structure, directly impacting current and prospective shareholders.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate changes, including new financial obligations and equity sales, which inherently carry integration and dilution risks for existing shareholders.
Analyst Insight
Investors should monitor subsequent filings for details on the financial obligations and equity sales, as these will clarify the dilution impact and the new company's debt structure post-merger with Serina Therapeutics.
Key Numbers
- $0.0001 — par value per share (This is the stated par value of AgeX Therapeutics' Common Stock.)
Key Players & Entities
- AgeX Therapeutics, Inc. (company) — the registrant filing the 8-K
- Serina Therapeutics, Inc. (company) — the company merging with AgeX Therapeutics
- February 1, 2024 (date) — date of the earliest event reported in the 8-K
- February 6, 2024 (date) — date the 8-K was filed
- $0.0001 (dollar_amount) — par value per share of AgeX Common Stock
Forward-Looking Statements
- The merger between AgeX Therapeutics and Serina Therapeutics will proceed as planned. (AgeX Therapeutics, Serina Therapeutics) — high confidence, target: 2024-12-31
- AgeX Therapeutics will experience significant changes in its corporate structure and business operations post-merger. (AgeX Therapeutics) — high confidence, target: 2024-12-31
FAQ
What is the primary purpose of this 8-K filing by AgeX Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report significant events that occurred on February 1, 2024, related to the creation of a direct financial obligation, unregistered sales of equity securities, and changes in control of the registrant, all in connection with its ongoing merger with Serina Therapeutics, Inc.
What specific items did AgeX Therapeutics, Inc. report under Item Information in this 8-K?
AgeX Therapeutics, Inc. reported 'Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant', 'Unregistered Sales of Equity Securities', 'Changes in Control of Registrant', and 'Other Events' under Item Information in this 8-K.
What is the par value of AgeX Therapeutics, Inc.'s Common Stock?
The par value of AgeX Therapeutics, Inc.'s Common Stock is $0.0001 per share.
On which exchange is AgeX Therapeutics, Inc.'s Common Stock registered?
AgeX Therapeutics, Inc.'s Common Stock (trading symbol AGE) is registered on the NYSE American exchange.
What is the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 1, 2024.
Filing Stats: 3,200 words · 13 min read · ~11 pages · Grade level 19.9 · Accepted 2024-02-06 16:05:20
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share AGE NYSE American Check
- $500,000 — , AgeX Therapeutics, Inc. ("AgeX") drew $500,000 of its credit available under the Amend
- $12.00 — on Stock being equal to or greater than $12.00 per share (on a post-reverse stock spli
Filing Documents
- form8-k.htm (8-K) — 60KB
- 0001493152-24-005085.txt ( ) — 238KB
- age-20240201.xsd (EX-101.SCH) — 3KB
- age-20240201_lab.xml (EX-101.LAB) — 33KB
- age-20240201_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGEX THERAPEUTICS, INC. Date: February 6, 2024 By: /s/ Andrea E. Park Chief Financial Officer